Heron Therapeutics Share Price (NASDAQ: HRTX)

$1.34

▲

-0.05

(-3.6%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Heron Therapeutics Stock chart to analyse performance

Heron Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$1.34
Today's High:$1.41
$1.34
0.0%
Downside
Day's Volatility :4.96%
Upside
4.96%
52 Weeks Low:$1.04
52 Weeks High:$2.68
$1.34
22.39%
Downside
52 Weeks Volatility :61.19%
Upside
50.0%

Heron Therapeutics Stock Returns

Period	Heron Therapeutics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-30.05%	3.6%	0.0%
6 Months	-39.73%	-7.7%	0.0%
1 Year	-21.97%	-12.6%	0.0%
3 Years	-68.31%	9.5%	-4.7%

Heron Therapeutics, Inc. Key Stats

Check Heron Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$1.39
Open	$1.38
Today's High	$1.41
Today's Low	$1.34
Market Capitalization	$213.1M
Today's Volume	$1.1M
52 Week High	$2.68
52 Week Low	$1.04
Revenue TTM	$149.7M
EBITDA	$3.6M
Earnings Per Share (EPS)	$-0.01
Profit Margin	-0.62%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-2408.88%

Stock Returns calculator for Heron Therapeutics Stock including INR - Dollar returns

The Heron Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Heron Therapeutics investment value today

Current value as on today

₹74,714

Returns

₹25,286

(-25.29%)

Returns from Heron Therapeutics Stock

₹30,570 (-30.57%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Heron Therapeutics Stock

100%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Heron Therapeutics Stock from India on INDmoney has increased by 100% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Heron Therapeutics, Inc.

Name
Holdings %
Name
Holdings %
Rubric Capital Management LP
17.43%
BlackRock Inc
5.59%
Vanguard Group Inc
5.53%
Adage Capital Partners Gp LLC
5.12%
Velan Capital Investment Management LP
4.56%
Palisade Capital Management LLc
3.45%

Analyst Recommendation on Heron Therapeutics Stock

Rating

Trend

Buy

90%Buy

10%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Heron Therapeutics(by analysts ranked 0 to 5 stars)

Heron Therapeutics Share Price Target

What analysts predicted

Upside of 254.48%

Target:

$4.75

Current:

$1.34

Heron Therapeutics share price target is $4.75, a slight Upside of 254.48% compared to current price of $1.34 as per analysts' prediction.

Heron Therapeutics Stock Insights

Price Movement
In the last 1 month, HRTX stock has moved down by -24.6%
Decreasing Revenue
Revenue is down for the last 3 quarters, 40.78M → 37.2M (in $), with an average decrease of 4.5% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, 3.66M → -2.38M (in $), with an average decrease of 109.2% per quarter
HRTX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 100.0%
HRTX vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 178.2%
Price to Sales
ForHRTX every $1 of sales, investors are willing to pay $1.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Heron Therapeutics, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$146.0M	↑ 88.41%
Net Income	$-204.7M	↑ 14.49%
Net Profit Margin	-140.27%	↑ 90.57%

	FY20	Y/Y Change
Revenue	$88.6M	↓ 39.28%
Net Income	$-224.4M	↑ 9.61%
Net Profit Margin	-253.2%	↓ 112.93%

	FY21	Y/Y Change
Revenue	$86.3M	↓ 2.59%
Net Income	$-217.7M	↓ 3.02%
Net Profit Margin	-252.08%	↑ 1.12%

	FY22	Y/Y Change
Revenue	$107.7M	↑ 24.7%
Net Income	$-134.5M	↓ 38.2%
Net Profit Margin	-124.93%	↑ 127.15%

	FY23	Y/Y Change
Revenue	$127.0M	↑ 17.99%
Net Income	$-110.6M	↓ 17.81%
Net Profit Margin	-87.02%	↑ 37.91%

	FY24	Y/Y Change
Revenue	$144.3M	↑ 13.57%
Net Income	$-13.6M	↓ 87.72%
Net Profit Margin	-9.41%	↑ 77.61%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$34.7M	↑ 1.28%
Net Income	$-3.2M	↓ 70.53%
Net Profit Margin	-9.11%	↑ 22.22%

	Q2 FY24	Q/Q Change
Revenue	$36.0M	↑ 3.91%
Net Income	$-9.2M	↑ 192.25%
Net Profit Margin	-25.64%	↓ 16.53%

	Q3 FY24	Q/Q Change
Revenue	$32.8M	↓ 8.92%
Net Income	$-4.8M	↓ 47.5%
Net Profit Margin	-14.78%	↑ 10.86%

	Q4 FY24	Q/Q Change
Revenue	$40.8M	↑ 24.29%
Net Income	$3.7M	↓ 175.56%
Net Profit Margin	8.98%	↑ 23.76%

	Q1 FY25	Q/Q Change
Revenue	$38.9M	↓ 4.61%
Net Income	$2.6M	↓ 28.06%
Net Profit Margin	6.77%	↓ 2.21%

	Q2 FY25	Q/Q Change
Revenue	$37.2M	↓ 4.38%
Net Income	$-2.4M	↓ 190.36%
Net Profit Margin	-6.4%	↓ 13.17%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$84.3M	↑ 68.83%

	FY20	Y/Y Change
Profit	$52.4M	↓ 37.82%

	FY21	Y/Y Change
Profit	$40.3M	↓ 23.12%

	FY22	Y/Y Change
Profit	$52.8M	↑ 30.93%

	FY23	Y/Y Change
Profit	$61.9M	↑ 17.31%

	FY24	Y/Y Change
Profit	$105.6M	↑ 70.55%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$26.2M	↑ 7.71%

	Q2 FY24	Q/Q Change
Profit	$25.5M	↓ 2.75%

	Q3 FY24	Q/Q Change
Profit	$23.4M	↓ 8.45%

	Q4 FY24	Q/Q Change
Profit	$30.6M	↑ 30.84%

	Q1 FY25	Q/Q Change
Profit	$30.4M	↓ 0.35%

	Q2 FY25	Q/Q Change
Profit	$27.3M	↓ 10.19%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-124.6M	↓ 35.05%
Investing Cash Flow	$-21.8M	↓ 92.18%
Financing Cash Flow	$186.4M	↓ 47.87%

	FY20	Y/Y Change
Operating Cash Flow	$-184.8M	↑ 48.35%
Investing Cash Flow	$209.0M	↓ 1059.26%
Financing Cash Flow	$9.1M	↓ 95.12%

	FY21	Y/Y Change
Operating Cash Flow	$-203.4M	↑ 10.03%
Investing Cash Flow	$32.7M	↓ 84.34%
Financing Cash Flow	$156.0M	↑ 1613.65%

	FY22	Y/Y Change
Operating Cash Flow	$-146.9M	↓ 27.76%
Investing Cash Flow	$-3.3M	↓ 110.16%
Financing Cash Flow	$75.1M	↓ 51.89%

	FY23	Y/Y Change
Operating Cash Flow	$-58.8M	↓ 59.98%
Investing Cash Flow	$18.0M	↓ 641.37%
Financing Cash Flow	$54.1M	↓ 27.91%

	FY24	Y/Y Change
Operating Cash Flow	$-22.5M	↓ 61.68%
Investing Cash Flow	$18.7M	↑ 4.0%
Financing Cash Flow	$940.0K	↓ 98.26%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-9.5M	↓ 487.62%
Investing Cash Flow	$1.3M	↓ 114.46%
Financing Cash Flow	$11.0K	↓ 94.47%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-4.6M	↓ 51.62%
Investing Cash Flow	$2.0M	↑ 60.25%
Financing Cash Flow	$492.0K	↑ 4372.73%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$3.4M	↓ 173.22%
Investing Cash Flow	$4.0M	↑ 93.85%
Financing Cash Flow	$14.0K	↓ 97.15%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-11.8M	↓ 449.45%
Investing Cash Flow	$11.4M	↑ 187.61%
Financing Cash Flow	$423.0K	↑ 2921.43%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-8.9M	↓ 24.7%
Investing Cash Flow	$2.3M	↓ 80.09%
Financing Cash Flow	$64.0K	↓ 84.87%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-10.9M	↑ 22.53%
Investing Cash Flow	$7.3M	↑ 222.66%
Financing Cash Flow	$781.0K	↑ 1120.31%

Heron Therapeutics Technicals Summary

Sell

Neutral

Buy

Heron Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Heron Therapeutics, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Heron Therapeutics, Inc.	-20.12%	-39.73%	-21.97%	-68.31%	-90.12%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Heron Therapeutics, Inc.	NA	NA	-0.18	-0.03	-24.09	0.0	NA	-0.18
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Heron Therapeutics, Inc.	Buy	$213.1M	-90.12%	NA	-0.62%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.

Organization	Heron Therapeutics
Employees	122
CEO	Mr. Craig Alexander Collard
Industry	Health Technology

Key Management of Heron Therapeutics, Inc.

Name	Title
Mr. Craig Alexander Collard	CEO & Director
Ms. Ira Duarte	Executive VP & CFO
Dr. William P. Forbes Pharm. D., Pharm.D.	Executive VP & Chief Development Officer
Mr. Mark E. Hensley	Executive VP & COO
Melissa Jarel	Executive Director of Legal
Mr. Ryan Craig	Vice President of Marketing
Mr. John Aiken	Executive Director of People Management & Training
Dr. John C. Arthur Ph.D.	Senior Vice President of Manufacturing & Supply
Mr. Robert Sullivan	Senior Vice President of Oncology Care Franchise & Commercial Operations
Mr. Brett Fleshman	Chief Business Officer

Important FAQs about investing in HRTX Stock from India :

What is Heron Therapeutics share price today?

Heron Therapeutics share price today is $1.34 as on August 30, 2025 at 1:29 am IST at the close of the market. Heron Therapeutics share today touched a day high of $1.41 and a low of $1.34.

What is the 52 week high and 52 week low for Heron Therapeutics share?

Heron Therapeutics share touched a 52 week high of $2.68 and a 52 week low of $1.04. Heron Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $1.34, lower by 50% versus the 52 week high.

How to invest in Heron Therapeutics Stock (HRTX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Heron Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Heron Therapeutics Shares that will get you 1.1194 shares as per Heron Therapeutics share price of $1.34 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Heron Therapeutics Stock (HRTX) from India?

Indian investors can start investing in Heron Therapeutics (HRTX) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Heron Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Heron Therapeutics share’s latest price of $1.34 as on August 30, 2025 at 1:29 am IST, you will get 7.4627 shares of Heron Therapeutics. Learn more about fractional shares .

What are the returns that Heron Therapeutics has given to Indian investors in the last 5 years?

Heron Therapeutics stock has given -90.12% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?